%0 Journal Article
%T Could knee inflammatory synovitis be induced by pembrolizumab?
%A Alison Gizinski
%A Fade Mahmoud
%A John T Wilkinson
%A John Vander Schilden
%A Neriman Gokden
%A Sanjaya Viswamitra
%J Journal of Oncology Pharmacy Practice
%@ 1477-092X
%D 2018
%R 10.1177/1078155217701292
%X Pembrolizumab, a selective anti-PD-1 humanized monoclonal antibody, reactivates T cells to fight cancer. Immune-related adverse events such as autoimmune colitis, pneumonitis, hepatitis, nephritis, hypophysitis, and thyroiditis may occur during, or weeks to months after therapy. Pemprolizumab-induced synovitis is rarely reported. With the wide use of immunotherapy to treat cancers, physicians need to be aware of this rare immune-related adverse event and provide immediate treatment to avoid permanent joint damage
%K Pemprolizumab
%K melanoma
%K autoimmune arthritis
%K synovitis
%U https://journals.sagepub.com/doi/full/10.1177/1078155217701292